77results about How to "Predict prognosis" patented technology

There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.

The present invention relates to a Y-type nucleotide probe having two probe portions on a single body such that it can be widely used for genotype testing and analysis with improved sensitivity, specificity, and accuracy, as well as to a DNA microarray, kit, and gene analysis method using the y-probe. The Y-probe of the invention is configured with five portions, comprising: a left probe portion, a left stem portion, a linker, a right stem portion, and a right probe portion. The DNA microarray of the present invention may have improved testing accuracy as it can perform a simultaneously overlapping test on the same gene or a simultaneous test on two different target genes. In particular, by simultaneously testing a target gene and a control gene in one spot, analysis errors can be reduced, quantitative analysis is made possible, and standardization is facilitated. The Y-probe of the present invention can be used for genotype analysis and gene expression analysis, as well as for mutation and SNP analysis, and can thus be broadly used for the diagnosis and prognosis of diseases and for genetic diagnosis for determining a course of treatment, etc.

This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)-RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue.

The present invention relates to a gene for predicting or diagnosing the prognosis of early-stage breast cancer and to a use thereof, and more specifically relates to a genetic marker for predicting or diagnosing the prognosis of breast cancer, including TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3, member A2) or HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) for providing information necessary for predicting or diagnosing the prognosis of a breast cancer patient. The genetic marker of the present invention allows the prediction or diagnosis of the prognosis of a breast cancer patient, and can therefore advantageously be used for the purpose of providing a direction as to the future course of breast cancer treatment, including a decision on whether anticancer therapy is necessary.

The invention provides application of a PD1 (programmed cell death 1)-CTLA4 (cytotoxic T lymphocyte-associated antigen-4) and / or PDL2 (programmed cell death 1 ligand 2)-CTLA4 for preparing a kit forpredicting AML (acute myeloid leukemia) prognosis. On the basis of the invention, an inventor discovers PD1 and CTLA4 in the bone marrow of an AML patient for the first time, the expression situationof the PLD2 and the CTLA4, and the prognosis correlation of an AML patient. When a simultaneous expression ratio of the PD1 to the CTLA4 and / or the PDL2 to the CTLA4 is high, a result indicates thata possibility of poor AML patient clinical prognosis is large. The combination of the PD1 and the CTLA4 and / or a combined expression ratio of the PDL2 to the CTLA4 has an important guidance meaning for making a plan for the prognostic judgment and clinic treatment scheme of the AML patient, more clinic prognosis research data is provided for the AML patient to realize the combined application ofimmune checkpoint inhibitors PD1-CTLA4 and PDL2-CTLA4, and the invention has a wide application prospect.